Dr. Ai on the FDA Approval of Mogamulizumab in CTCL

Wei Z. Ai, MD, hematologist, University of California, San Francisco, discusses the FDA approval of mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy.

• Kategorija